RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

PHASE2CompletedINTERVENTIONAL
Enrollment

513

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

November 13, 2023

Study Completion Date

January 29, 2024

Conditions
Bloodstream Infections
Interventions
DRUG

Cefiderocol

2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).

OTHER

Best Available Therapy

Standard of care was determined by the investigator

Trial Locations (19)

Unknown

Westmead Hospital, Sydney

Princess Alexandra Hospital, Brisbane

Royal Brisbane and Womens Hospital, Brisbane

The Prince Charles Hospital, Brisbane

Austin Hospital, Melbourne

Universiti Sains Malaysia, Kubang Kerian

University of Malaya Medical Centre, Kuala Lumpur

Changi General Hospital, Singapore

National University Hospital Singapore, Singapore

Singapore General Hospital, Singapore

Tan Tock Seng Hospital, Singapore

Taichung Veterans General Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

Tri-Service General Hospital, Taipei

Chang Gung Memorial Hospital, Taoyuan District

Ramathibodi Hospital, Bangkok

Siriraj Hospital, Bangkok

Khon Kaen University, Khon Kaen

Istanbul Medipol Üniversitesi, Istanbul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Shionogi

INDUSTRY

lead

The University of Queensland

OTHER

NCT03869437 - RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI | Biotech Hunter | Biotech Hunter